Cardiac Marker Testing Market Research Report Information By Product Type (Reagents And Kits And Instruments, (Chemiluminescence, Immunofluorescence, ELISA, Immunochromatography), By Biomarker Type (Troponin I And T, Creatine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein And Other Cardiac Biomarkers), By Diseases (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis And Ischemia), By End User (Laboratory Testing Facilities, (Hospital Labs, Reference Labs, Contract T

Global Cardiac Marker Testing Market Overview

Cardiac Marker Testing Market Size was valued at USD 4.5 Billion in 2023. The Cardiac Marker Testing market industry is projected to grow from USD 4.9 Billion in 2024 to USD 10.4 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.70% during the forecast period (2024 - 2032). Increased awareness and screening are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Marker Testing Market Trends

• 
  

  Growing awareness and screening are driving the market growth

  
  

Market CAGR for cardiac marker testing is being driven by growing awareness and screening. Public health initiatives and educational campaigns raise awareness about the importance of regular health screenings, including cardiac marker testing, among individuals at risk for heart-related conditions. Increased awareness encourages initiative-taking healthcare-seeking behavior, leading to higher demand for cardiac marker tests in both clinical and community settings. By emphasizing the significance of timely diagnosis and intervention, these programs empower healthcare providers and patients to prioritize heart health, ultimately contributing to the expansion of the cardiac marker testing market as more individuals seek preventive care and screening services.

Rising healthcare expenditure fuels the growth of the cardiac marker testing market by facilitating increased investment in diagnostic technologies and healthcare infrastructure. As healthcare spending continues to climb globally, there is greater capacity for healthcare providers to invest in advanced cardiac marker testing assays and equipment. This enables the adoption of state-of-the-art diagnostic tools in hospitals, clinics, and laboratories, enhancing the availability and accessibility of cardiac marker testing services. Additionally, higher healthcare expenditure often correlates with improved healthcare access and quality, leading to greater utilization of cardiac marker tests for cardiovascular disease screening, diagnosis, and monitoring. The allocation of resources towards preventive care and disease management, supported by increased healthcare spending, drives market demand for cardiac marker testing as a crucial component of comprehensive cardiovascular healthcare strategies.

Strategic collaborations and partnerships are instrumental in propelling the cardiac marker testing market forward by fostering innovation, expanding market reach, and accelerating product development. By joining forces with research institutions, healthcare organizations, and other industry stakeholders, companies in the cardiac marker testing sector can access complementary expertise, resources, and technologies to enhance their product offerings. Collaborations enable the pooling of knowledge and resources for the development of novel cardiac marker assays with improved sensitivity, specificity, and clinical utility. Furthermore, partnerships facilitate market expansion by leveraging each partner's distribution networks and market presence to reach new customer segments and geographic regions. Through strategic alliances, companies can capitalize on synergies, mitigate risks, and capitalize on emerging opportunities, driving growth and competitiveness in the cardiac marker testing market.

For instance, SRL Diagnostics, a prominent network of diagnostic laboratories in India, introduced "Heart Assure," a cutting-edge high-sensitivity Troponin I (hsTnI) test designed to assess the likelihood of a cardiac event among individuals at risk. This hsTnI test is a straightforward blood examination capable of detecting minute quantities of Troponin I (picogram/ml) in the bloodstream. By doing so, it accurately forecasts the occurrence of a cardiac event or injury, furnishing a heart health risk score and estimating the probability of future cardiac events.

Cardiac Marker Testing Market Segment Insights

Cardiac Marker Testing Product Type Insights

The Cardiac Marker Testing Market segmentation, based on product type, includes Reagents and Kits and Instruments (-Chemiluminescence, -Immunofluorescence, -ELISA, and Immunochromatography. In 2023, the Reagents and Kits segment dominated the market, accounting for 30% of market revenue due to their widespread usage in laboratories and healthcare facilities. These products offer convenience, accuracy, and consistency in cardiac marker testing procedures. Additionally, reagents and kits are essential components for various diagnostic assays, including immunoassays and molecular diagnostics, providing reliable results for the detection and quantification of cardiac biomarkers. Their accessibility, ease of use, and critical role in diagnostic workflows contribute to their substantial market share in cardiac marker testing.

Cardiac Marker Testing Biomarker Type Insights

The Cardiac Marker Testing Market segmentation, based on biomarker type, includes Troponin I and T, Creatine kinase-MB, Brain Natriuretic peptide, Myoglobin, High-sensitivity C-reactive protein, and Other Cardiac Biomarkers. In 2023, the Troponin I and T category generated the most income due to their high specificity and sensitivity for detecting cardiac injury. They are considered gold standards for diagnosing acute myocardial infarction (heart attack) and assessing cardiac risk in various clinical settings. Additionally, guidelines from medical societies recommend their use, further boosting their adoption. The widespread recognition of Troponin I and T biomarkers as reliable indicators of cardiac damage cements their dominance in the market.

Cardiac Marker Testing Diseases Insights

The Cardiac Marker Testing Market segmentation, based on diseases, includes Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Ischemia. In 2023, the myocardial infarction category generated the most income due to its high prevalence and severity. MI, commonly known as a heart attack, is a leading cause of morbidity and mortality worldwide. Consequently, there is a substantial demand for accurate and timely diagnostic tools to detect MI and assess its severity. Cardiac marker testing plays a critical role in the diagnosis, risk stratification, and management of MI, driving its dominance in the market.

Figure 1: Cardiac Marker Testing Market, by Diseases, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cardiac Marker Testing End User Insights

The Cardiac Marker Testing Market segmentation, based on end user, includes Laboratory Testing Facilities (Hospital Labs, Reference Labs, Contract Testing Labs), Point-Of-Care Testing Facilities and Academic Institutions. In 2023, the Laboratory Testing Facilities category generated the most income. These facilities offer a comprehensive range of diagnostic services, including cardiac marker testing, making them primary destinations for patients requiring cardiovascular assessments. Additionally, laboratory testing facilities often employ skilled personnel and house advanced instrumentation, ensuring accurate and timely test results. Their accessibility, reliability, and ability to handle a high volume of tests contribute to their dominance in the market.

Cardiac Marker Testing Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America has secured the largest market share in the cardiac marker testing market due to several factors. Firstly, the region boasts advanced healthcare infrastructure and high healthcare expenditure, facilitating the widespread adoption of cardiac marker testing technologies. Additionally, the prevalence of cardiovascular diseases, coupled with stringent regulatory standards and favorable reimbursement policies, drives market growth. Furthermore, the presence of key market players and ongoing research and development initiatives contribute to the region's dominance in cardiac marker testing.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Cardiac Marker Testing Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Cardiac Marker Testing market accounts for the second-largest market share due to the increasing prevalence of cardiovascular diseases. Europe has emerged as the second-largest market for cardiac marker testing due to several key factors. The region benefits from a well-established healthcare system with a focus on preventive care and early disease detection. Additionally, the increasing prevalence of cardiovascular diseases, coupled with aging populations, drives demand for cardiac marker testing. Moreover, supportive government initiatives, robust research and development activities, and strategic collaborations between industry players contribute to the growth of the cardiac marker testing market in Europe. Further, the German Cardiac Marker Testing market held the largest market share, and the UK Cardiac Marker Testing market was the fastest growing market in the European region.

The Asia-Pacific Cardiac Marker Testing Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest compound annual growth rate (CAGR) in the cardiac marker testing market due to several factors. Firstly, the region has a large and rapidly growing population, leading to an increasing prevalence of cardiovascular diseases. Additionally, rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about preventive healthcare drive demand for cardiac marker testing. Furthermore, expanding access to advanced diagnostic technologies and supportive government initiatives contribute to the accelerated growth of the cardiac marker testing market in the Asia Pacific. Moreover, China’s Cardiac Marker Testing market held the largest market share, and the Indian Cardiac Marker Testing market was the fastest growing market in the Asia-Pacific region.

Cardiac Marker Testing Key Market Players & Competitive Insights

Leading players in the cardiac marker testing market are focusing on strategic initiatives such as product launches, partnerships, and acquisitions to strengthen their market position. They are investing in research and market developments to innovate new cardiac marker assays with enhanced sensitivity and specificity. Additionally, companies are expanding their geographic presence through collaborations and distribution agreements. Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, and bioMérieux. These efforts aim to meet the increasing demand for accurate and reliable cardiac marker testing solutions.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Cardiac Marker Testing industry to benefit clients and increase the market sector. In recent years, the Cardiac Marker Testing industry has offered some of the most significant advantages to troponin I and T. Major players in the Cardiac Marker Testing market, including Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, bioMérieux, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Randox Laboratories, Thermo Fisher Scientific, Becton, Dickinson and Company and Other, are attempting to increase market demand by investing in research and development operations.

Roche Diagnostics, a division of the Swiss multinational healthcare company Roche, is a leading provider of diagnostic solutions worldwide. With a strong focus on innovation and research, Roche Diagnostics offers a comprehensive portfolio of cardiac marker testing products, including high-sensitivity Troponin assays and other cardiac biomarker tests. The company's cardiac marker testing solutions are known for their accuracy, reliability, and clinical utility in diagnosing and monitoring cardiovascular diseases. Roche Diagnostics also provides integrated laboratory systems and informatics solutions to healthcare providers, ensuring seamless workflow and improved patient care. With a global presence and a commitment to advancing healthcare diagnostics, Roche Diagnostics continues to play a significant role in shaping the cardiac marker testing market.

Abbott Laboratories is a renowned global healthcare company that operates in various segments, including diagnostics, medical devices, nutrition, and pharmaceuticals. In the cardiac marker testing market, Abbott Laboratories is a key player, offering a wide range of innovative diagnostic solutions. The company's portfolio includes high-sensitivity cardiac troponin assays, point-of-care testing devices, and integrated laboratory systems for cardiac marker testing. Abbott's cardiac marker testing products are known for their accuracy, sensitivity, and ease of use, enabling healthcare providers to efficiently diagnose and manage cardiovascular diseases. With a strong commitment to research and development, along with a global distribution network, Abbott Laboratories continues to make significant contributions to the advancement of cardiac marker testing, ultimately improving patient outcomes worldwide.

Key Companies in the Cardiac Marker Testing market include

• Roche Diagnostics


• Abbott Laboratories


• Siemens Healthineers


• bioMérieux


• Ortho Clinical Diagnostics


• Bio-Rad Laboratories


• Randox Laboratories


• Beckman Coulter


• Thermo Fisher Scientific


• Becton, Dickinson and Company

Cardiac Marker Testing Industry Developments

July 2022: Siemens Healthineers introduced the Atellica CI 1900 Analyzer, a clinical chemistry and immunoassay testing system, along with a scaled-down version of its existing Atellica solution for clinical chemistry and immunoassay testing, during the Annual Scientific Meeting and Clinical Lab Expo.

June 2022: SCIEX, a prominent player in life science analytical technologies and a subsidiary of Danaher Corporation introduced Zeno SWATH DIA, marking a significant advancement in biomarker discovery and translation processes.

Cardiac Marker Testing Market Segmentation

Cardiac Marker Testing Product Type Outlook

• Reagents and Kits


• Instruments
  
  
  
  • Chemiluminescence
  
  
  • Immunofluorescence
  
  
  • ELISA
  
  
  • Immunochromatography
  
  
  
  

Cardiac Marker Testing Biomarker Type Outlook

• Troponin I and T


• Creatine Kinase-MB


• Brain Natriuretic Peptide


• Myoglobin


• High-Sensitivity C-Reactive Protein


• Other Cardiac Biomarkers

Cardiac Marker Testing Diseases Outlook

• Myocardial Infarction


• Congestive Heart Failure


• Acute Coronary Syndrome


• Atherosclerosis


• Ischemia

Cardiac Marker Testing End User Outlook

• Laboratory Testing Facilities
  
  
  
  • Hospital Labs
  
  
  • Reference Labs
  
  
  • Contract Testing Labs
  
  
  
  


• Point-Of-Care Testing Facilities


• Academic Institutions

Cardiac Marker Testing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America